Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients

NCT04276558 is registered in ClinicalTrials.gov with RECORDATI GROUP as lead sponsor.

NCT NCT04276558
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04276558 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety and Pharmacokinetics of 3 Doses of REC 0/0559 Eye Drops for the Treatment of Stage 2 (Moderate) and 3 (Severe) Neurotrophic Keratitis in Adult Patients
Lead sponsor
RECORDATI GROUP
Phase
Phase 2
Overall status
Completed
Start date
October 13, 2020
Completion date
April 29, 2024
Enrollment
108 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

neurotrophic keratitis